Spravato Operations Series
The Spravato Prior Authorization Playbook
Before a commercial payer authorizes Spravato for treatment-resistant depression, it usually wants two failed antidepressant trials documented by drug, dose, duration and outcome, plus a current PHQ-9 or similar score and a REMS-certified site. That part is predictable. Approvals are time-boxed or session-boxed, and the reauthorization, which asks whether treatment is working, is where most programs lose money.
Prior Authorization Is Not A One-Time Event
Most clinics treat the Spravato prior authorization as a gate you pass through once, at intake. That’s wrong, and it’s the root of most Spravato revenue loss. A Spravato authorization has a start date, an end date, a session count and a renewal cycle, and the patient’s treatment usually outlives it. The labeled dosing schedule shows why. It’s twice-weekly sessions in weeks 1 to 4, weekly in weeks 5 to 8, then every one to two weeks in maintenance, potentially for a year or more. Very few payers authorize all of that up front.
If you run the authorization as a lifecycle (initial approval, tracked utilization, reauthorization on a deadline), the program stays funded. Run it as a checkbox and you’ll eventually treat patients on dead auths.
The Initial Authorization: What Payers Want To See
Criteria vary by payer, but commercial PA requirements for treatment-resistant depression cluster around a predictable documentation set:
- Diagnosis and severity: A documented MDD diagnosis with current severity, usually supported by a standardized instrument: PHQ-9 is the most commonly requested; some payers accept or prefer MADRS or HAM-D scores.
- Failed-trial history: Documentation that the patient has failed at least two adequate trials of oral antidepressants in the current episode, with drug names, doses, durations and outcomes. Vague “tried several medications” notes get pended. Specific drug/dose/duration tables get approved.
- Treatment plan: The intended dosing schedule (induction cadence and target dose), the REMS-certified setting where treatment will occur, and, depending on indication and payer policy, whether esketamine is adjunctive to an oral antidepressant or, under the January 2025 FDA approval, used as monotherapy.
- Prescriber and site details: Some payers verify REMS certification status, site of care, and the prescriber’s network status before approving. A credentialing gap can stall a clinically clean PA, so check the prescriber’s network status before you submit.
Build a PA packet template once for each payer, and reuse it. The clinics that get fast approvals aren’t writing better prose. They’re answering the payer’s checklist in the payer’s order.
Reauthorization: The Window That Actually Matters
Initial approvals are commonly time-boxed (often one to six months, payer-dependent) or session-boxed (a set number of administrations), or both. Reauthorization typically asks a different question than the initial PA: not “does this patient qualify?” but “is this working?” Expect to document:
- Response evidence: Serial symptom scores, the same PHQ-9 (or equivalent) trail you started at baseline. If your workflow doesn’t capture scores at a regular cadence, reauthorization is where that gap becomes a payment problem.
- Utilization consistency: Sessions delivered roughly on protocol. Long unexplained gaps invite “is continued treatment medically necessary?” pushback.
- Continued-need rationale: Why maintenance continues (response maintained, relapse risk, a taper plan where relevant).
Operationally, the rule we run: start the reauthorization when roughly 30 days or 4 sessions of runway remain, whichever comes first. Payer turnaround is unpredictable; the buffer is the point.
The Auth-Expiry Failure Mode
The most common Spravato revenue failure goes like this. A patient stabilizes into every-other-week maintenance. Treatment is routine; everyone relaxes. The authorization that covered induction quietly ends, a date passes, or session 24 of 24 gets used and nothing in the clinic’s system flags it, because the schedule keeps generating appointments either way. The clinic delivers three, four, six more sessions. Then the denials arrive, weeks later, all at once: services not authorized. Retro-authorization sometimes works and often doesn’t, and each unpaid session costs you the drug as well as the staff time.
Nobody made a clinical mistake. It’s a structural gap. Scheduling and authorization status live in different systems, and nothing connects them. The fix is checking every scheduled session against a live auth that still has sessions left. We cover the tracking mechanics in Spravato authorization tracking, and the tooling we build for it on the custom software page.
Payer Variation Patterns
Commercial Payers
Almost all of them require PA, usually with the TRD documentation set above. Watch the benefit split. Some plans cover the drug under the medical benefit (buy-and-bill). Others push it through the pharmacy benefit via a REMS-certified specialty pharmacy, and the PA may live on that side. In our Oregon program we track distinct auth behaviors across Regence, Providence Health Plan and Optum Behavioral Health (UnitedHealthcare). Assume each payer plays by its own rules until you’ve seen otherwise.
Medicare
Traditional Medicare generally doesn’t run a commercial-style PA gate. Coverage is governed by MAC billing articles and documentation requirements, and Medicare pays through bundled G-codes (G2082/G2083) rather than separate drug claims. Medicare Advantage plans usually do require prior authorization and behave more like commercial payers. Never assume “Medicare” means “no auth” without checking which Medicare.
Medicaid And CCOs
State Medicaid programs and managed plans (in Oregon, CCOs) vary the most: PA criteria, preferred acquisition pathway, and covered settings differ by state and by plan. Some require the specialty-pharmacy pathway outright. Verify plan-specific policy in writing before the first induction. Medicaid retro-auth is the least forgiving of the three lanes.
These are patterns, not guarantees. Payer policies change, and the individual plan document is what counts when it disagrees with anything here. The coding side of these differences is covered in our Spravato billing guide.
Common Questions
How Long Does A Spravato Prior Authorization Take?
Usually a few business days to two weeks for commercial payers when the packet’s complete. It takes longer when records are missing or the request pends for clinical review. Incomplete failed-trial documentation is the most frequent cause of delay.
How Many Antidepressant Failures Do Payers Require For Spravato?
Most payers mirror the treatment-resistant depression definition: at least two adequate trials of oral antidepressants in the current episode, documented with drug, dose, duration, and outcome. Some payers add step requirements or augmentation-trial expectations, so check the specific policy.
When Should We Start A Spravato Reauthorization?
Our operating rule is to start when roughly 30 days or 4 sessions of authorization runway remain, whichever comes first. Payer turnaround varies too much to cut it closer, and a lapsed auth mid-maintenance means unpaid sessions with real drug cost attached.
Does Medicare Require Prior Authorization For Spravato?
Traditional Medicare generally does not use a commercial-style PA process, though MAC billing-article and documentation requirements still apply. Medicare Advantage plans usually do require prior authorization. Always confirm which type of Medicare coverage the patient has.
Can We Get Paid Retroactively If An Authorization Lapsed?
Sometimes. Some payers allow retro-authorization or an appeal with good-cause documentation, but many don’t, and approval is never assured. Treat retro-auth as damage control, not a plan. Tracking that prevents the gap is far cheaper.
What Symptom Scales Should We Use For Spravato Documentation?
PHQ-9 is the most commonly requested by payers; MADRS and HAM-D also appear in policies. Whichever you use, capture it at baseline and on a regular cadence, because reauthorization approvals lean heavily on a visible score trail.
Make The Reauthorization Date Hard To Miss
An Automation Program puts this lifecycle into the systems your team already uses: each patient’s authorization dates and sessions left next to the schedule, reauthorization deadlines in front of the person who owns them, and the score trail ready when the payer asks. It’s $5,000, or 5 monthly payments of $1,000, and optional Automation Care after go-live starts at $400 a month. For the claims side, see our billing prices by practice size.